National Systemic Anti-Cancer Therapy (SACT) consent forms – forms for gynaecological cancers published
The regimen-specific consent forms for gynaecological cancers have been published on the Cancer Research UK (CRUK) website. There are 24 forms for this tumour group:
- BEP (5 day)
- Bevacizumab
- Carboplatin
- Carboplatin-Etoposide
- Carboplatin-Paclitaxel
- Cisplatin
- Cisplatin + Radiotherapy
- Cisplatin-Etoposide
- Cisplatin-Fluorouracil
- Cisplatin-Fluorouracil + Radiotherapy
- Cisplatin-Paclitaxel
- Cisplatin-Topotecan
- Doxorubicin
- Doxorubicin-Cisplatin
- EP (Etoposide-Cisplatin)
- Etoposide (oral)
- Gemcitabine
- Gemcitabine-Carboplatin
- Gemcitabine-Cisplatin
- Liposomal doxorubicin (Caelyx®)
- Liposomal doxorubicin (Caelyx®) – Carboplatin
- Olaparib
- Paclitaxel (day 1, 8 & 15)
- Topotecan (IV)
Please visit www.cruk.org/sact_consent to view and download the forms. Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent.
The National Chemotherapy Board published guidance on consent for SACT in July 2016 and recommends use of the regimen-specific forms in the UK. The forms have been produced with support from CRUK.
Please do not hesitate to contact Rena Chauhan (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: [email protected].
Rena Chauhan
4 January 2017
